Brief: Foghorn Therapeutics Announces New Data Demonstrating Brd9 Degradation In Patient Tumor Biopsies And Discloses New Selective Cbp Program
26/10/2022 12:03
Oct 26 (Reuters) - Foghorn Therapeutics Inc. FHTX.O :
* FOGHORN THERAPEUTICS ANNOUNCES NEW DATA DEMONSTRATING BRD9
DEGRADATION IN PATIENT TUMOR BIOPSIES AND DISCLOSES NEW
SELECTIVE CBP PROGRAM
* FOGHORN THERAPEUTICS INC. - INITIAL PHASE 1 DATA OF
FHD-609 SHOW
DEGRADATION OF BRD9 IN ON-TREATMENT METASTATIC TUMOR SYNOVIAL
SARCOMA BIOPSIES
* FOGHORN THERAPEUTICS INC. - NEW PRECLINICAL DATA
DEMONSTRATE
FHD-609 IS HIGHLY SELECTIVE, WITH NO OFF-TARGET IMID
NEOSUBSTRATE DEGRADATION ACTIVITY
Source text for Eikon: ID:nGNX26M4Fx
Further company coverage: FHTX.O
((Reuters.Briefs@thomsonreuters.com;))